From antidepressants to psychedelics: revisiting the pharmacology of so-called serotoninergic treatments

Recent years have seen a resurgence of interest in serotoninergic psychedelics as potential treatment for diverse psychiatric disorders. Here, we will delve into the molecular mechanisms of drugs used to treat depression and obsessive-compulsive disorder (OCD), with implications on the mechanism of action of so-called ''serotoninergic'' psychedelics as well as selective serotonin reuptake inhibitors (SSRIs). In particular, we argue that the pharmacokinetic and pharmacodynamic properties of SSRIs suggest that the inhibition of the serotonin transporter (SERT) alone does not provide a comprehensive account of their clinical effects. On the contrary, the SSRI posology required to treat depression and OCD is consistent with their major molecular target(s) displaying an SSRI affinity much lower than SERT. Such is the case for the tyrosine receptor kinase B (TrkB), recently described as a putative target for drugs with antidepressant effects. TrkB might thus provide a unifying framework for understanding the therapeutic effects of antidepressant drugs. We finally discuss the pharmacological implications of this hypothesis on the therapeutical potential of psychedelics.

Authors

Institutions

Publication Details

Journal
arXiv (Cornell University)
Published
2026-11-16
DOI
https://doi.org/10.48550/arxiv.2611.20834
Primary Topic
Psychedelics and Drug Studies
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

From antidepressants to psychedelics: revisiting the pharmacology of so-called serotoninergic treatments

Luc Mallet, Marc Gielen, Daniela Duarte Domingues, Eric Burgui{è}re et al.
arXiv (Cornell University)
Psychedelics and Drug Studies
preprint

From antidepressants to psychedelics: revisiting the pharmacology of so-called serotoninergic treatments

Luc Mallet, Marc Gielen, Daniela Duarte Domingues, Eric Burgui{è}re, Kevin Swierkosz- Lenart
preprint en

Abstract

Recent years have seen a resurgence of interest in serotoninergic psychedelics as potential treatment for diverse psychiatric disorders. Here, we will delve into the molecular mechanisms of drugs used to treat depression and obsessive-compulsive disorder (OCD), with implications on the mechanism of action of so-called ''serotoninergic'' psychedelics as well as selective serotonin reuptake inhibitors (SSRIs). In particular, we argue that the pharmacokinetic and pharmacodynamic properties of SSRIs suggest that the inhibition of the serotonin transporter (SERT) alone does not provide a comprehensive account of their clinical effects. On the contrary, the SSRI posology required to treat depression and OCD is consistent with their major molecular target(s) displaying an SSRI affinity much lower than SERT. Such is the case for the tyrosine receptor kinase B (TrkB), recently described as a putative target for drugs with antidepressant effects. TrkB might thus provide a unifying framework for understanding the therapeutic effects of antidepressant drugs. We finally discuss the pharmacological implications of this hypothesis on the therapeutical potential of psychedelics.

arXiv (Cornell University)
Inserm (FR), Université Paris-Est Créteil (FR)
Psychedelics and Drug Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon